Part,  Chapter, Paragraph

 1   II,     5.  3.  7|            access to cancer drugs” (Jonsson et al, 2007) highlights
 2   II,     5.  3.  9|           Cancer Inst 94:606-616.~ ~Jonsson B, Wilking N (2007): Summary.
 3   II,     5.  4.  1|           Spain, Sweden and the UK (Jonsson et al 2002). For these 8
 4   II,     5.  4.  1|              55%). A Swedish study (Jonsson et al 2000) observed that
 5   II,     5.  4.  8| Diabetologia, 2002; 45(7): S5-12.~ ~Jonsson PM (2000), Marke LA, Nystrom
 6   II,     5.  5.  3|            21-27.~Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J (
 7   II,     5.  6.  3|            for productivity losses (Jonsson and Husberg, 2000). In France
 8   II,     5.  6.  6|             Petterson C, De Laet C, Jonsson B (2004): Mortality after
 9   II,     5.  6.  6|             Osteoporos Int 15:38-42~Jonsson D and Husberg M (2000):
10   II,     5.  6.  6|       Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002): Ten-year
11   II,     5.  6.  6|        Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (
12   II,     5.  8.  7|    Andersson F, Borg S, Ericsson A, Jonsson E, Lundback B (2002): Costs
13   II,     5.  8.  7|              264-272.~ ~Lindberg A, Jonsson AC, Ronmark E, Lundgren
14   II,     5.  8.  7|             Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, Larsson LG,
15   II,     5.  8.  7|              Ronmark E, Jonsson AC, Jonsson E, Larsson LG, Andersson